BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28

• 

  Business

  Axovant CEO David Hung Abruptly Exits, COO and Several Directors Also Resign

  Axovant shares plunged after Hung abruptly resigned as CEO and also stepped down from his seat on the company board of directors.

  February 12, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  3 Drugs That Could Make-or-Break AbbVie

  A look at three drug approvals of vital importance to the company this year.

  February 12, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Bio NC

  3 Biotech Gems to Stock Up on This Month

  A look at a few bargains in today’s choppy market.

  February 12, 2018

   · 

  1 min read
• 

  Veryan’s Stent Meets Safety, Efficacy Endpoints After One Year

  The device, which is shaped to mimic the natural geometry of human vasculature, compared favorably with drug-coated balloons and stents.

  February 12, 2018

   · 

  1 min read
• Business

  Week in Review: Tsinghua University Invests $276M in Cambridge UK Biohub

  Beijing’s Tsinghua University will invest $276M in a JV to build a new biohub in the UK’s Cambridge Science Park.

  February 12, 2018

   · 

  1 min read
• Beijing InnoCare Pharma Raises $55M in Vivo-led Round

  InnoCare is developing a portfolio of novel drugs for cancer and autoimmune diseases, using a combination of in-licensing and internal research.

  February 12, 2018

   · 

  1 min read
• Policy

  Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for Firdapse

  Resubmission of NDA for Firdapse on schedule for end of the first quarter.

  February 12, 2018

   · 

  6 min read
• Drug Development

  Santen Presents Phase I/II Data on DE-122 (Carotuximab) in Patients With Refractory Wet Age-Related Macular Degeneration

  No serious adverse events were reported.

  February 12, 2018

   · 

  3 min read
• Policy

  U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizer’s Third-Generation ALK Inhibitor Lorlatinib

  Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted and granted Priority Review to the company’s New Drug Application for lorlatinib.

  February 12, 2018

   · 

  9 min read
• Business

  Saama’s Life Science Ecosystem Helps Partners Leverage Its Award-Winning Clinical Data Analytics Solutions Without Replacing Existing Vendors

  Saama Technologies, a leading clinical data analytics company, has launched the Life Science Ecosystem for its partners.

  February 12, 2018

   · 

  4 min read